Tyrosine kinase receptor-mediated signal transduction and cancer treatment

Yaoxue Xuebao

Volumn 37, Issue 3, 2002, Pages 229-234

  Zhu, Xiao Feng ^a   Liu, Zong Chao ^a   Zeng, Yi Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Anticancer drugs; Signal transduction; Tyrosine kinase receptor

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

ANIMAL; ARTICLE; BREAST TUMOR; DRUG ANTAGONISM; HUMAN; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 0041736269     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Xu NZ. Oncology (WJg) [M]. Beijing: People's Medical Publishing House, 1999.80-96.
2. Fantl WJ. Signaling by receptor tyrosine kinases [J]. Ann Rev Biochem, 1993,62:453-462.
3. Ethier SP. Growth factor synthesis and human breast cancer progression [J]. J Natl Cancer Inst, 1995,87(13):964-973.
4. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis [J] . Oncogene, 2000,19(53):6122-6129.
5. Honegger AM, Szapary D, Schmidt A, et al. A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis [J]. Mol Cell Blol, 1987,74(12):4568-4571.
6. Price JT, Tiganis T, Agarwal A, et al. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism [J]. Cancer Res, 1999,59(21):5475 -5478.
7. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer [J]. EMBO J, 1996,15(2): 254-264.
8. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions [J]. EMBO J, 1996,15(10):2452-2467.
9. Alimandi M, Wang LM, Bottaro D, et al. Epidermal growth factor and betacellulin mediate signal transduction through coexpressed ErbB2 and ErbB3 receptors [J]. EMBO J, 1997, 16(18):5608-5617.
10. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma [J]. Clin Cancer Res, 2000,6(12):4874-4884.
11. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells [J]. Clin Cancer Res , 2000,6(9): 3739-3747.
12. Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide [J]. Clin Cancer Res , 2000,6(11):4343-4350.
13. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer [J]. Proc Am Soc Clin Oncol, 1998(abstr),17:97a.
14. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 + /MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial [J]. Pro Am Soc Clin Oncol, 1998(abstr),17:98a.
15. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents [J]. Drugs, 2000,60(Suppl 1):25-32.
16. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase [J]. Clin Cancer Res, 2000,6(12):4885-4892.
17. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice [J]. J Pharm Exp Ther, 1999,291(2):739-748.
18. Vincent PW, Bridges AJ, Dykes DJ, et al. Anticancer efficacy of the irreversible EGFR tyrosine kinase inhibitor PD0169414 against human turmor xenografts [J]. Cancer Chemother Pharmacol, 2000,45(3):231-238.
19. Zhu XF, Zeng YX, Yang D. Discovery of HER2/neu tyrosine kinase inhibitor through computer-aided drugs design approach and its biological activity [J]. Chin J Cancer (J® E), 2001,20(4):341-347.
20. Zhu XF, Zeng YX, Yang D. Effect of ST2325 on cell cycle in erbB2-overexpressing breast cancer cells and its mechanism [J]. China Oncol (* B JS & ££), 2001,11(2):97-100.
21. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types [J]. Cancer Res, 1999,59(1):99-106.
22. Eckhardt SG. Phase I and Pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors [J]. J Clin Oncol, 1999,17(4):1095-1104.
23. Tamanoi F. Inhibitors of ras farnesyltransferases [J]. TIBS, 1993,18(9):349-353.
24. Tahir SK, Gu WZ, Zhang HC, et al. Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue [J]. Eur J Cancer, 2000, 36(9):1161-1170.
25. Christopher JB, Jean DG, Bernard B, et al. Novel conformational extended naphthalene-based inhibitor of farnesyltransferase [J]. J Med Chem, 1997,40(12):1763-1767.
26. Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy [J]. Cancer Chemother Pharmacol, 1999,43(Suppl):61-68.
27. Rajeev SB, Dinesh CP, Manorama MP, et al. Rational design of protein carboxylic acid based bisubstrate inhibitors of ras farnesyl protein transferase [J]. Bioorg Med Chem Lett, 1994,4(17):2107-2112.
28. Haag JD, Lindstrom MJ, Gould MN. Limonene-induced regression of mammary carcinomas [J]. Cancer Res, 1992, 52(14):4021-4026.
29. Tamanoi F. Inhibitors of ras farnesyltransferases [J]. Trends Biochem Sci, 1993,18(9):349-353.
30. Lobell RB, Kohl NE. Pre-clinical development of farnesyltransferase inhibitors [J]. Cancer Metastasis Rev, 1998,117(2):203-210.
31. Holmlund JT, Monia BP, Kwoh TJ, et al. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development [J]. Curr Opin Mol Ther, 1999,1(2):372-385.
32. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo [J]. Nat Med, 1999,5(7):810-816.
33. Hu L, Zaloudek C, Mills GB, et al. In vivo and in vitro ovarian cancer growth inhibition by phosphatidylinositol 3-kinase inhibitor (LY294002) [J]. Clin Cancer Res, 2000,6 (3):880-886.
34. Gibbs JB. Anticancer drug targets: growth factors and growth factor signaling [J]. J Clin Invest, 2000,105(1):9-13.